All In Biotech

Drug Trial Radar · NCT05755113

A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

A Phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall.

Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Apr 13, 2023

Primary completion

Jan 2027

Study completion Jun 2027

Sponsor

Lead sponsor
QBiotics Group LimitedIndustry
Sponsor type
Industry
First posted
Mar 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase IIa open label study evaluating the preliminary efficacy of intratumoural tigilanol tiglate in advanced and/or metastatic soft tissue sarcoma of the extremities and body wall.

Conditions

  • Soft Tissue Sarcoma

Interventions

  • Tigilanol TiglateDrug

    Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tumour ResponseTime frame: 6 months
  2. ORR as determined by RECISTTime frame: 3 and 6 months post initial treatment (Stage 2 only)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Centre

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.